(ZNTL) Zentalis Pharmaceuticals - Ratings and Ratios
Oncology, Kinase, Inhibitors, Oral, Pipeline
ZNTL EPS (Earnings per Share)
ZNTL Revenue
Description: ZNTL Zentalis Pharmaceuticals
Zentalis Pharmaceuticals LLC (NASDAQ:ZNTL) is a biotechnology company listed on the NASDAQ stock exchange. As a common stock, ZNTL is classified under the Biotechnology sub-industry according to the GICS classification, indicating its primary business is in the development of pharmaceuticals.
The companys market capitalization stands at $103.88 million, suggesting it is a relatively small-cap stock. The absence of a Price-to-Earnings (P/E) ratio, either current or forward, indicates that the company is not profitable, which is common for companies in the biotechnology sector that are often in the development phase. The Return on Equity (RoE) is significantly negative at -51.62%, further highlighting the companys current unprofitability and potentially significant operational costs or losses.
Key economic drivers for Zentalis Pharmaceuticals include the progress of its drug pipeline, clinical trial outcomes, and the potential for FDA approvals. Success in these areas can significantly impact the stocks performance. Investors should monitor news related to the companys research and development milestones, as these can be critical KPIs influencing stock price movements.
From a trading perspective, ZNTLs stock has shown volatility, with an Average True Range (ATR) of 0.08, representing a 4.87% daily price movement. Its beta of 1.716 suggests that the stock is more volatile than the overall market, indicating a higher risk profile. Average trading volume is substantial at 562,800 shares, suggesting decent liquidity. Monitoring moving averages (SMA20, SMA50, SMA200) and trading volumes can provide insights into the stocks trend and potential entry or exit points.
Investors should focus on upcoming catalysts such as clinical trial results, potential product launches, and strategic partnerships, which can drive the stocks performance. Given the companys negative earnings and high volatility, a thorough risk assessment is crucial. Investors must weigh the potential upside against the significant risks associated with investing in a non-profitable biotechnology stock.
ZNTL Stock Overview
| Market Cap in USD | 123m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-04-03 |
ZNTL Stock Ratings
| Growth Rating | -90.4% |
| Fundamental | 32.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -60.3% |
| Analyst Rating | 3.70 of 5 |
ZNTL Dividends
Currently no dividends paidZNTL Growth Ratios
| Growth Correlation 3m | 78.1% |
| Growth Correlation 12m | -80.9% |
| Growth Correlation 5y | -92.2% |
| CAGR 5y | -60.67% |
| CAGR/Max DD 3y | -0.63 |
| CAGR/Mean DD 3y | -1.01 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | -75.58 |
| Beta | 0.992 |
| Volatility | 82.99% |
| Current Volume | 505.2k |
| Average Volume 20d | 708.2k |
| Stop Loss | 1.3 (-12.8%) |
| Signal | -1.18 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-162.8m TTM) > 0 and > 6% of Revenue (6% = 1.61m TTM) |
| FCFTA -0.49 (>2.0%) and ΔFCFTA -6.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1015 % (prev 874.1%; Δ 140.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.43 (>3.0%) and CFO -151.1m > Net Income -162.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 7.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (72.0m) change vs 12m ago 1.34% (target <= -2.0% for YES) |
| Gross Margin 96.05% (prev 96.87%; Δ -0.81pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 6.37% (prev 8.68%; Δ -2.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -23.60
| (A) 0.78 = (Total Current Assets 311.6m - Total Current Liabilities 39.0m) / Total Assets 351.7m |
| (B) -3.21 = Retained Earnings (Balance) -1.13b / Total Assets 351.7m |
| warn (B) unusual magnitude: -3.21 — check mapping/units |
| (C) -0.43 = EBIT TTM -179.5m / Avg Total Assets 421.7m |
| (D) -14.63 = Book Value of Equity -1.13b / Total Liabilities 77.2m |
| Total Rating: -23.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.21
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.15 = 2.49 |
| 5. Debt/Ebitda -0.23 = -2.50 |
| 6. ROIC - WACC -66.99% = -12.50 |
| 7. RoE -51.62% = -2.50 |
| 8. Rev. Trend 23.79% = 1.19 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 41.41% = 1.04 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ZNTL shares?
Over the past week, the price has changed by -14.86%, over one month by +5.67%, over three months by +2.05% and over the past year by -52.70%.
Is Zentalis Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZNTL is around 0.67 USD . This means that ZNTL is currently overvalued and has a potential downside of -55.03%.
Is ZNTL a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ZNTL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.2 | 315.4% |
| Analysts Target Price | 6.2 | 315.4% |
| ValueRay Target Price | 0.8 | -49% |
Last update: 2025-09-05 05:09
ZNTL Fundamental Data Overview
CCE Cash And Equivalents = 303.4m USD (Cash And Short Term Investments, last quarter)
P/S = 4.5915
P/B = 0.4494
Beta = 1.716
Revenue TTM = 26.9m USD
EBIT TTM = -179.5m USD
EBITDA TTM = -178.4m USD
Long Term Debt = 38.2m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.63m USD (from shortTermDebt, last quarter)
Debt = 41.8m USD (Calculated: Short Term 3.63m + Long Term 38.2m)
Net Debt = 91.0k USD (from netDebt column, last quarter)
Enterprise Value = -138.3m USD (123.4m + Debt 41.8m - CCE 303.4m)
Interest Coverage Ratio = unknown (Ebit TTM -179.5m / Interest Expense TTM 0.0)
FCF Yield = -123.7% (FCF TTM -171.1m / Enterprise Value -138.3m)
FCF Margin = -636.8% (FCF TTM -171.1m / Revenue TTM 26.9m)
Net Margin = -605.9% (Net Income TTM -162.8m / Revenue TTM 26.9m)
Gross Margin = 96.05% ((Revenue TTM 26.9m - Cost of Revenue TTM 1.06m) / Revenue TTM)
Tobins Q-Ratio = 0.12 (Enterprise Value -138.3m / Book Value Of Equity -1.13b)
Interest Expense / Debt = 14.23% (Interest Expense 5.95m / Debt 41.8m)
Taxrate = 21.0% (US default)
NOPAT = -179.5m (EBIT -179.5m, no tax applied on loss)
Current Ratio = 7.99 (Total Current Assets 311.6m / Total Current Liabilities 39.0m)
Debt / Equity = 0.15 (Debt 41.8m / last Quarter total Stockholder Equity 274.5m)
Debt / EBITDA = -0.23 (Net Debt 91.0k / EBITDA -178.4m)
Debt / FCF = -0.24 (Debt 41.8m / FCF TTM -171.1m)
Total Stockholder Equity = 315.3m (last 4 quarters mean)
RoA = -46.28% (Net Income -162.8m, Total Assets 351.7m )
RoE = -51.62% (Net Income TTM -162.8m / Total Stockholder Equity 315.3m)
RoCE = -50.77% (Ebit -179.5m / (Equity 315.3m + L.T.Debt 38.2m))
RoIC = -56.92% (NOPAT -179.5m / Invested Capital 315.3m)
WACC = 10.07% (E(123.4m)/V(165.2m) * Re(9.67%)) + (D(41.8m)/V(165.2m) * Rd(14.23%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 90.91 | Cagr: 2.18%
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -171.1m)
Revenue Correlation: 23.79 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -491.6
EPS Correlation: 41.41 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -40.76
Additional Sources for ZNTL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle